A Phase 1 Study of a Combined Cytotoxic and Immune-Stimulatory Therapy in Pediatric and Young Adult Patients With Recurrent, Primary Malignant Brain Tumors
This early trial tests a new combination therapy using modified viruses and an antiviral medication to help the immune system fight recurrent brain tumors. The goal is to find the safest and most effective dose for children and young adults.
This study is open to patients aged 3 to 39 with specific recurrent cancerous brain tumors that doctors can safely remove with surgery. Participants must meet certain weight and health requirements.
Participants will undergo surgery to remove the tumor, receive the experimental gene therapies and antiviral medication, and have regular check-ups that include scans, tests, and questionnaires.
The study is currently recruiting patients and takes place in Ann Arbor, Michigan, United States.
- 1Tests a combined gene and immune therapy for recurrent brain tumors.
- 2Involves surgery to remove the tumor and administering study medications.
- 3Currently recruiting patients aged 3 to 39 in Ann Arbor, Michigan.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.